The focus on biomarkers of Aβ and tau pathology rather than the clinical diagnosis of AD allows to investigate the effect of different mixtures of both pathologies on FDG-PET changes and cognitive impairment. The gene discussed is MAPT; the disease is Alzheimer disease.